Tat, a regulatory protein encoded by the HIV genome, plays a unique role in the emergence of the virus from the latent state. Viruses with a defective Tat gene cannot proliferate and do not show cytopathic effects. Tat stimulates HIV-1 gene expression by increasing the rate of transcription and length of transcripts (20, 24, 54, 57) .
Tat-induced activation of HIV-1 promoter action is mediated via a virus sequence known as the trans-activator response (tar) element, extending from Ϫ17 to ϩ42 bp (17, 57) . Inactivation of tar greatly decreases the activation by Tat. The minimum Tat-responsive element is reported to be the sequence from ϩ19 to ϩ42 (32) . Tat binds to tar RNA and then interacts with a transcriptional initiation complex (9, (16) (17) (18) composed of both DNA-and RNA-binding proteins, which regulates transcription from the LTR (5, 25, 28, 42, 54) .
Tat has other modes of action. Expression of Tat in human cells in culture led to overexpression of cellular genes encoding cytokines (12, 48, 51, 55) . Tat also trans-activated the tar-less TNF promoter (12) and potentiated TNF action (61) . Cytokine overproduction by HIV-infected, Tat-producing cultured CD4 ϩ human T lymphocytes and monocytes was reported (12, 48, 51) . Consistent with these results, HIV-1-infected, Tat-producing patients have significant elevations of cytokine levels in plasma (11, 21, 37, 38, 50) and cytokine-specific mRNAs (21) . These cytokines increase virus replication in HIV-1-infected cells and thereby play an important role in the pathogenesis of the disease (45) (46) (47) . These results suggest that this viral protein could influence the HIV-1 promoter, by a tar-independent mechanism.
Cellular gene products can activate HIV replication, as well as cytokine production. A low level of activation is caused by compounds such as TNF-␣, a cytokine that activates the NF-B sequences in the HIV promoter. We propose that an important part of Tat activation of HIV is through tar-independent activation of cytokine gene transcriptions, producing cytokines such at TNF-␣ which activate NF-B in the HIV promoter.
Different cellular transactivators and LTR enhancer elements demonstrate various levels of interaction with Tat and trans-activation of the HIV-1 promoter (5, 33, 36, 60) . ''Superactivation'' of HIV-1 LTR-driven gene expression is induced by the concerted interaction of cellular trans-activator NF-B and viral protein Tat (4, 6, 15, 34, 35, 39) . The interaction between SP1 and Tat similarly superactivates HIV-1 gene expression (31, 33) . We have reported that NF-B and Tat/tar cooperate to superactivate HIV-1 LTR-driven reporter gene expression in cultured human CD4 ϩ Jurkat T lymphocytic cells. This superactivation was observed in the absence of an externally added activator of NF-B and was somewhat increased by these activators (6) . These results suggest that Tat activates NF-B. Mutations of these motifs decrease activation to a few percent of the wild-type value.
We have also defined roles of cellular genes and of cytokines such as TNF-␣ in the Tat/NF-B-induced superactivation of HIV-1 promoter and virus replication by using specific inhibitors of NF-B, Tat, and TNF-␣ actions (6) . Compounds that interfere with such multifactorial interplay inhibit viral gene expression and replication (reference 7 and unpublished data). The tar-dependent and cytokine-based activations together set up positive-feedback loops. Agents have been found that block these pathways at three different steps and that are more inhibitory in combinations than is any one.
Whether and how Tat can activate the HIV-1 promoter by a tar-independent mechanism is unclear. These results prompt us to make three postulations. (i) One action of Tat in inducing HIV-1 promoter activation is mediated via a pathway which is independent of the viral element tar. (ii) By this pathway, Tat induces overexpression of cellular cytokine genes that activate NF-B, which exists as an inactive complex in the cytoplasm of cells other than B cells (26, 56 ; for a review, see reference 27). (iii) NF-B in turn activates the HIV-1 promoter and also cytokine promoters and establishes an auto-up-regulatory loop (Fig. 1) .
The experimental goal of this study is to examine these possibilities by establishing a tar-independent pathway of Tatinduced trans-activation of the HIV-1 promoter and thereby to define the in vivo relevance of the two modes of action of Tat, i.e., tar dependent and tar independent, in the context of Tat/ NF-B-induced superactivation of the HIV-1 promoter. We provide evidence to support two separate pathways of action of Tat. We postulate that their synergism induces superactivation of the viral promoter and of virus replication.
MATERIALS AND METHODS
Abbreviations. HIV-1, human immunodeficiency virus type 1; Tat, trans-activator of transcription; tar; trans-activating response element; LTR, long terminal repeat; TNF-␣, tumor necrosis factor alpha; PMA, phorbol 12-myristate 13-acetate; CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility shift assay; PTX, pentoxifylline, IL-1 and IL-6, Interleukin-1 and interleukin-6.
Cells. Jurkat CD4 ϩ T lymphocytes and a stable transfectant of Jurkat cells in which the simian virus 40 promoter-driven tat gene is constitutively expressed (Jurkat-Tat; obtained from J. Sodroski, Dana-Farber Cancer Institute, Boston, Mass.) were maintained in RPMI 1640 (GIBCO/BRL, Gaithersburg, Md.) tissue culture medium supplemented with 10% fetal bovine serum at 37ЊC in an atmosphere of 5% CO 2 and 95% air. G418 (Sigma Chemical Co., St. Louis, Mo.) at 400 g/ml (100% potency) was added to the culture medium of Jurkat-Tat cells.
Reagents. PTX, Ro24-7429, and Gö-6976 were gifts from Hoechst-Roussel Pharmaceuticals, Sommerville, N.J., Hoffman-La Roche, Nutley, N.J., and Parke-Davis Co., Ann Arbor, Mich., respectively. DEAE-dextran, acetyl coenzyme A, Geneticin (G418), and PMA were from Sigma Chemical Co., St. Louis, Mo. TNF-␣ and anti-human TNF-␣ antibody were from Endogen, Cambridge, Mass. [ Transfections. Transient transfections of Jurkat cells with the specified fusion plasmids were performed by the DEAE-dextran procedure as described previously (8) . Results of all the transient-transfection studies were normalized for transfection efficiency by cotransfection of pSV-lacZ plasmid and measurement of ␤-galactosidase activity along with CAT activity in the control and treated cell extracts (40) . Simian virus 40 promoter-driven ␤-galactosidase activity was not influenced by the treatment conditions described in this study. The procedures for extract preparation, protein content (10), CAT activity, and ␤-galactosidase activity were described previously (7, 8) .
EMSA. Nuclear extracts from control and treated cells were prepared as described by Dignam et al. (23) . Reaction conditions with 32 P-labeled doublestranded oligonucleotide carrying the NF-B motif and EMSA conditions were the same as described previously (7) . Details of the quantitation of CAT activity, ␤-galactosidase activity, and autoradiographic signals of EMSA and Northern (RNA) blot analysis are described in the figure legends.
RESULTS

Activation of HIV LTR by NF-B and by
Tat. Basal reporter CAT activity, using our standard assay conditions (7, 8) and the unmutated pHIV-1 LTR-CAT plasmid, was stimulated only about three-to fourfold by PMA or TNF-␣ ( Fig. 2A) . A dramatically greater induction of CAT was observed when Tat was provided to the wild-type HIV promoter construct as reported previously (6) . Tat induced an up-regulation of HIV-1 promoter with functional NF-B (Fig. 2B ) that was 70-fold higher than the basal level in unstimulated cells. PMA or TNF-␣ further stimulated this Tat-induced superactivation by less than twofold, to a lesser degree than the activation by these compounds observed in the absence of Tat ( Fig. 2A) . These results suggest that when both pathways of activation by Tat are functional they synergize and that the second pathway operates through production of a subsaturating level of TNF-␣.
A second, tar-independent, pathway of activation of HIV-1 promoter by Tat. The two pathways of activation by Tat are shown schematically in Fig. 1 . The Tat/tar-mediated pathway is designated as tar dependent (Fig. 1, step 1) . The tar-independent, cytokine-mediated pathway is designated the auto-upregulatory loop (Fig. 1 , steps 2 to 9).
The tar-dependent first pathway was studied by transient transfection of Jurkat cells with the fusion plasmid pHIV-1 LTR-mut-NF-B-CAT (43, 44) cotransfected with the Tatexpressing vector pSVTat (14) followed by measurements of CAT reporter gene expression (6) (Fig. 3A) . Activation of the HIV-1 promoter via NF-B transcription was not operative in this assay because of the specific mutations in the LTR. HIV-1 LTR-driven reporter CAT activity was undetectable in control transfections with pSV-lacZ (lane designated by 0 Tat) or the plasmid backbone without the insert (data not shown), suggesting that contributions by other trans-activators such as SP1 were very minimal and undetectable in this system. The input expression vector pSV-Tat demonstrated a concentration-dependent stimulation of reporter gene expression, which correlated with elevated levels of Tat-specific mRNA measured in transiently transfected Jurkat cells. A stimulation of the basal (0.9%) reporter gene expression following transfection of the cells with pSVTat was observed, ranging from three-to fivefold in three separate transfection experiments. TNF-␣ or PMA did not further stimulate HIV-1 LTR-driven reporter gene expression in these three experiments (Fig. 3A) , demonstrating that these cytokines were not directly involved in this Tat/tar-mediated pathway of activation of the NF-B-defective HIV-1 promoter.
We propose a second pathway for Tat in up-regulating the HIV-1 promoter, which does not involve interaction with the nascent RNA product of the viral gene tar. This tar-independent pathway was studied by transiently cotransfecting Jurkat cells with a fusion plasmid lacking the tar element (pHIV-LTR-⌬tar-CAT) and pSV-Tat and measuring LTR-driven reporter CAT activity. The results (Fig. 3B ) demonstrated a pSV-Tat plasmid concentration-dependent 3.5-fold stimulation of tar-less HIV-1 LTR-driven reporter gene expression above a low basal activity detected in the absence of Tat. This influence of Tat was observed in three separate experiments, and stimulation varied from three-to fivefold. About two-to threefold further stimulation of reporter gene expression by PMA and TNF-␣ was detected in all of these experiments, indicating a modest activation of HIV-1 promoter via the NF-B motifs. The stimulations by these substances of wildtype plasmid ( Fig. 2A) were also similar to those observed with pHIV-1 LTR ⌬tar-CAT plus or minus 10 g of pSVTat expression (Fig. 3B) . Both constructs have wild-type NF-B motifs. These results are consistent with the concept of production of TNF-␣ under the influence of Tat, which activates NF-B by the tar-independent pathway.
The influence of Tat, expressed from the indicated concentrations of input plasmid, on cell viability was examined in all of these three experiments. Tat at these concentrations was not cytotoxic to the host cells (Fig. 3C) .
Tat induces overexpression of cytokine genes. Since overexpression of genes encoding cytokines were detected in Tatproducing HIV-1-infected patients (22, 37) and cytokines are physiological activators of NF-B (26, 56) , the expression of cellular cytokine genes under the influence of Tat was the next focus of this study. We examined the level of expression of three cytokine genes, TNF-␣, IL-6, and IL-1, in cells in which Tat was either expressed from a transiently transfected expression vector pSVTat or in a transfectant of Jurkat cells that stably express Tat protein (14) . Figure 4A shows the levels of TNF-␣-, IL-6-, and IL-1-specific mRNA species as determined by Northern blot analysis under the influence of Tat protein, expressed from the indicated concentrations of the input pSVTat plasmid. The autoradiographic signals (Fig. 4A) were quantitated by densitometric scanning as described in the legend to Fig. 4 , and the results are presented in Fig. 4B . The levels of the TNF-␣-, IL-6-, and IL-1-specific mRNAs were elevated six-, three-, and twofold, respectively, concurrent with elevated Tat mRNA levels. Similar elevated levels of specific mRNAs under the influence of Tat were observed in three separate experiments. The 32 P-labeled unrelated gene 36B4 cDNA was used as the loading control (52) . To establish that the Tat gene was expressed in pSV-Tat-transfected cells, Tatspecific mRNA was measured; elevated levels of Tat mRNA corresponding to the increased concentrations of the input plasmid were observed ( Fig. 4A and B) . No Tat-specific mRNA was detected in untransfected Jurkat cells. Elevated levels of TNF-␣-specific mRNA were also detected in stable transfectants of Jurkat cells (Jurkat-Tat) that constitutively express Tat from a stably integrated plasmid (14) (Fig. 4C) . The level of actin mRNA was used as a loading control in this experiment.
Tat stimulates TNF promoter activity. The above results suggest that Tat either directly or indirectly stimulates TNF gene expression. To further examine this influence of Tat, we measured expression of the CAT gene in a fusion gene construct (pTNF-CAT-TNF) with 1,087 bp of 5Ј upstream region of mouse TNF gene, which has four NF-B motifs along with one SP1 motif, the TATA box, and is fused to the CAT gene (3). This flanking region is similar to that of the human TNF gene. The plasmid was cotransfected into Jurkat cells with different amounts of the Tat gene expression vector pSVTat. The results showed a concentration-dependent Tat stimulation of CAT activity (Fig. 5A) . In the middle part of each panel, . Some cells were treated with 20 ng of PMA per ml or 10 ng of TNF-␣ per ml for 18 and 4 h, respectively, before extracts were prepared 72 h after transfection, and enzyme assays (CAT and ␤-galactosidase) were performed as described previously (6, 8 results on the level of CAT activity in duplicate samples are shown, and these are quantitated by scanning of the thin-layer chromatography paper, which is shown as bar graphs in the lower part of these panels. This experiment was repeated three times, and similar stimulation, ranging from six-to eightfold, was detected. These results are in agreement with those reported by Buonaguro et al. (12) , who observed 1.4-to 4-fold stimulation of TNF promoter under the influence of Tat. These results with a tar-less TNF promoter confirm the concept that Tat can activate a promoter in the absence of a tar element, in accord with the concept of the second pathway of Tat action.
To examine the role of NF-B in this Tat activity, a fusion plasmid (pTNF-109-CAT-TNF) in which the 978-bp region of the promoter which includes the four NF-B motifs was deleted (3) was cotransfected with pSVTat (Fig. 5B) . The basal level of TNF promoter activity was somewhat higher in experiments carried out with fusion plasmid with a deleted (Ϫ978 bp) 5Ј end of the promoter. However, the stimulatory influence of Tat on TNF promoter was lost with the deletion of the NF-B motifs in this region. This result suggests that the NF-B motifs are important; however, it is also possible that deleted sequences other than the NF-B motifs are also involved in the Tat-induced activation of TNF promoter.
Anti-TNF-␣ antibody inhibits Tat-induced up-regulation of the HIV-1 promoter.
The above results suggest involvement of TNF-␣ in the Tat-induced activation of genes carrying NF-B, as mediated via a tar-independent second pathway. Evidence for TNF-␣ involvement was obtained by adding anti-TNF-␣ antibody to Jurkat cells transiently cotransfected with pHIV-1 LTR-⌬tar-CAT and pSV-Tat. Tat-induced activation of this tar-less HIV-1 promoter was reduced to the basal level by the presence of anti-TNF-␣ antibody, in a concentration-dependent fashion (Fig. 6A) . Similarly, NF-B/Tat-induced superactivation of the HIV-1 promoter, examined by transiently cotransfecting Jurkat cells with fusion plasmid pHIV-1 LTR-CAT and with pSV-Tat, was inhibited in the presence of even lower concentrations of anti-TNF-␣ antibody (Fig. 6B) . These results strongly suggest involvement of autocrine TNF-␣, overexpressed under the influence of Tat via the tar-independent pathway, in activation of the HIV-1 promoter. It is not clear at this stage how superactivation of HIV-1 promoter is more sensitive to anti-TNF-␣ antibody (Fig. 6B) . Results in Fig. 6C demonstrate that anti-TNF-␣ antibody was not cytotoxic at these concentrations.
Tat induces activation of NF-B. To verify that activation of NF-B is a result of Tat action via the second pathway, we examined the levels of active NF-B in Jurkat cells by using (14) . The NF-B motifs were mutated in the LTR sequence, so that activation by NF-B was not operational. Treatment of cells with PMA (20 ng/ml) and TNF-␣ (10 ng/ml) was carried out for 18 and 4 h, respectively. Preparation of cell extracts and measurement of CAT and ␤-galactosidase activity in 10-g protein aliquots were determined as described previously (8) . The results were quantitated by scanning the thin-layer chromatography paper in a Betascope 603 blot analyzer (Betagen, Waltham, Mass.). Normalized CAT activity is expressed as the percentage of [ EMSA to determine interaction between nuclear extracts and the 32 P-labeled motif. The retarded DNA-protein complex formed by interaction of the active NF-B with its motif within the 32 P-labeled synthetic oligonucleotide is indicated by the arrow (Fig. 7) . The specificity of this DNA-protein interaction was previously established in this laboratory by competition experiments with nonradioactive oligonucleotide carrying wildtype or mutated NF-B motifs (8) . The lower retarded complex that is routinely observed in this assay is apparently formed by the interaction of p50 dimers in the nuclear extracts with the radioactive oligonucleotide (53) .
A weak interacting band was detected from nuclear extract of Tat-nonexpressing Jurkat cells (Fig. 7A, lane 1) . Active NF-B in transiently transfected Jurkat cells was increasingly elevated by larger amounts of pSV-Tat (lanes 2 to 4). This Tat-induced stimulation was substantially reduced in the presence of anti-TNF-␣ antibody (lanes 5 to 8), suggesting a role of the secreted cytokine in Tat-induced activation of NF-B. Externally added TNF-␣ reversed this inhibitory influence of anti-TNF-␣ antibody (lanes 9 and 10). As shown previously (8) , the results in lanes 11 and 12 demonstrate the stimulatory influence of TNF-␣, by itself, on activation of NF-B. Figure  7B shows a quantitative representation of the results in Fig. 7A by densitometric scanning of the NF-B specific binding activity. Anti-TNF-␣ antibody did not influence HIV-1 LTR-driven reporter gene expression in cells in the presence of PMA or of TNF-␣ (data not shown).
Differential influences on the two modes of Tat-induced trans-activation of HIV-1 promoter. We used conditions that preferentially activate or block the two separate pathways of Tat activation of the HIV-1 promoter to distinguish between them. The results presented in Table 1 summarize the influence of seven agents on the HIV-1 promoter acting via (i) the tar-dependent pathway, (ii) the NF-B-dependent pathway (tar independent), and (iii) both pathways. The agents characterized as inhibitors of NF-B action are Gö-6976 (49) and PTX (7), which act via inhibition of protein kinase C. Ro24-7429 and Ro5-3335 have been characterized as inhibitors of Tat action (19, 29, 30) and also of Tat/NF-B-induced superacti- (2), and IL-6 (58) cDNA inserts were 32 P labeled by using a random-primed DNA-labeling kit (Boehringer Mannheim Biochemicals, no. 1004760) and were used for hybridization to identify specific mRNA species. The tar-independent action of Tat (on cells transfected with the fusion plasmid with its tar element deleted) was stimulated by Tat and also by TNF-␣ and PMA. This pathway was inhibited by PTX, Gö-6976, and anti-TNF-␣ antibody but not by Ro24-7429, suggesting that protein kinase C inhibitors such as PTX and Gö-6976, and also the antibody, inhibit only the tar-independent pathway and do not influence the tar-dependent pathway of activation by Tat. Ro24-7429, the Tat inhibitor, had just the opposite effect.
As reported previously (6), Tat expressed from cotransfected plasmid pSV-Tat greatly elevated CAT levels when the LTR sequence of the transfected fusion plasmid (pHIV-1 LTR-CAT) carried both wild-type NF-B motifs and the tar element. All these inhibitors blocked this NF-B/Tat-induced superactivation (Table 1) . These results demonstrated that inhibitors of either NF-B or Tat were effective when both pathways of Tat action were operative, a cellular state which is comparable to the HIV-1-infected one.
DISCUSSION
We postulate that the viral protein Tat initiates two chains of reactions following infection with HIV (Fig. 1) . Synergism between these two actions of Tat, mediated via separate pathways, is responsible for the superactivation of the HIV-1 promoter, viral gene expression, and virus replication. One involves the Tat/tar interaction, and the other starts a tarindependent pathway which overexpresses genes encoding cytokines such as TNF-␣, which activates NF-B through the specific receptor-mediated signaling mechanism. Active NF-B in turn closes the loops by trans-activating the HIV-1 and TNF promoters. Each pathway alone has minimal effects.
The end result of Tat action via the tar-independent cytokine pathway is the activation of NF-B, which plays a central role in linking the two pathways of Tat action by stimulating both HIV-1 and cytokine promoters. A recent study with normal T lymphocytes and a lymphoblastoid cell line (J-JHAN) suggests that Tat-mediated stimulation of the HIV-1 promoter is abso- 
a Jurkat cells were transfected with 10 g of the fusion plasmid pHIV-1 LTR-mut-NF-B-CAT and 5 g of pSV-Tat (pathway 1), 10 g of pHIV-1 LTR-⌬tar-CAT and pSV-Tat (pathway 2), and 5 g each of pHIV-1 LTR-CAT and pSV-Tat (pathway 3). At 24 h after transfection, the cells were treated with TNF-␣ (10 ng/ml) for 4 h or PMA (20 ng/ml) for 18 h.
b Treatments with Ro24-7429 (300 nM), Gö-6976 (300 nM), PTX (300 M), and anti-TNF-␣ antibody (10 ng/ml) were performed for 48 h. At 72 h after transfection and 48 h after drug treatments, the cell extracts were prepared and CAT activity in 10 g of protein from each extract was measured as described previously (6) . ϩϩϩ, strong activation; ϩ, activation, Ϫ, inhibition, 0, does not activate or inhibit; Gö, Gö-6976; Ro, Ro24-7429.
lutely dependent on NF-B response elements (1). We postulate that this requirement for Tat action is fulfilled by Tatinduced overexpression of cytokine genes via the tarindependent pathway, which turns on NF-B trans-activation.
The mechanism of the observed up-regulation of TNF promoter by Tat is not clearly understood. Buonaguro et al. (13) implicated a tar-like sequence immediately downstream of TATA in Tat-induced up-regulation of the TNF-␤ promoter, but the role of such a DNA sequence in the TNF-␣ gene has not been demonstrated. Furthermore, our results suggest that the remaining region of the TNF promoter lacking the NF-B motifs in a fusion gene construct that still contains SP1 and other immediate downstream sequences of the basic transcriptional complex is not sufficient to stimulate TNF promoter activity (Fig. 5B) . Activated NF-B is central to superactivation by Tat of the HIV-1 promoter and of cytokine promoters. These results are consistent with the concept that Tat-induced up-regulation of cytokines and the HIV-1 promoter operates via tar-independent and NF-B-dependent transcriptional activation. As both Tat-induced activation of NF-B and superactivation of the HIV-1 promoter are partly blocked by anti-TNF-␣ antibody, it may be concluded that Tat-induced TNF-␣ generated via the auto-up-regulatory loop plays a major role in the NF-B/Tat-induced superactivation of the HIV-1 promoter. 
